Src as a novel therapeutic target for endometriosis (2014)
- Authors:
- Autor USP: NOUSHMEHR, HOUTAN - FMRP
- Unidade: FMRP
- DOI: 10.1016/j.ygyno.2014.06.016
- Subjects: TRANSFORMAÇÃO CELULAR NEOPLÁSICA; ENDOMETRIOSE; NEOPLASIAS OVARIANAS; DOENÇAS DOS GENITAIS FEMININOS
- Language: Inglês
- Imprenta:
- Publisher place: Maryland Heights
- Date published: 2014
- Source:
- Título: Gynecologic Oncology
- ISSN: 0090-8258
- Volume/Número/Paginação/Ano: v. 135, n. 1, p. 100-107, 2014
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
LAWRENSON, Kate et al. Src as a novel therapeutic target for endometriosis. Gynecologic Oncology, v. 135, n. 1, p. 100-107, 2014Tradução . . Disponível em: https://doi.org/10.1016/j.ygyno.2014.06.016. Acesso em: 28 dez. 2025. -
APA
Lawrenson, K., Lee, N., Torres, H. A. M., Lee, J. M., Brueggmann, D., Rao, P. N., et al. (2014). Src as a novel therapeutic target for endometriosis. Gynecologic Oncology, 135( 1), 100-107. doi:10.1016/j.ygyno.2014.06.016 -
NLM
Lawrenson K, Lee N, Torres HAM, Lee JM, Brueggmann D, Rao PN, Noushmehr H, Gayther SA. Src as a novel therapeutic target for endometriosis [Internet]. Gynecologic Oncology. 2014 ; 135( 1): 100-107.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1016/j.ygyno.2014.06.016 -
Vancouver
Lawrenson K, Lee N, Torres HAM, Lee JM, Brueggmann D, Rao PN, Noushmehr H, Gayther SA. Src as a novel therapeutic target for endometriosis [Internet]. Gynecologic Oncology. 2014 ; 135( 1): 100-107.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1016/j.ygyno.2014.06.016 - Integrative analysis identifies functional prostate cancer risk SNPs in genomic regulatory regions defined as enhancers
- Genome-wide fingerprinting of regulatory chromatin to evaluate the tissue specific origins of high-grade serous ovarian cancer
- Epigenomic (DNA methylation and expression) signatures define subsets of both IDHmut and IDHwt glioma with distinct clinical outcomes
- Molecular patterns at regulatory elements diferentially methylated in glioma
- Clinical data that matters: a distillation of neuro-oncology clinical trial inclusion criteria using machine learning
- Genomic landscape of idh-mutant primary glioblastomas shows distinct clinical and molecular features and that CDKN2A should be supplemented with MGMTp and G-CIMP for precise prognostication
- Tumor-myeloid cell interactions are dynamic and influence the evolutionary trajectory of adult diffuse glioma
- DNA methylation signature associated with risk of recurrence in papillary thyroid carcinoma
- DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management
- SpidermiR: an R/Bioconductor package for integrative analysis with miRNA data
Informações sobre o DOI: 10.1016/j.ygyno.2014.06.016 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
